M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post...
M0240 - Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Access to this feature is available in the following products:
- Find-A-Code Essentials
- HCC Plus
- Find-A-Code Elite
- Find-A-Code Premium
- Find-A-Code Professional
- Find-A-Code Facility Base
- Find-A-Code Facility Complete
- Find-A-Code Facility Plus
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Additional Code Information includes:
|
Save time with a Professional or Facility subscription! You will be able to see the most common modifiers billed to Medicare along with this code.
View historical information about the code including when it was added, changed, deleted, etc. Access to this feature is available in the following products:
|
Subscribers may add their own notes as well as "Admin Notes" visible to all subscribers in their account. Access to this feature is available in the following products:
Subscribers may add their own notes as well as "Admin Notes" visible to all subscribers in their account. |
Subscribers will see related documentation, coding and billing tips. Access to this feature is available in the following products:
|
Medicare COVID-19 Fees
Important: This product is not authorized for administration until further notice by the FDA.
Labeler | Vaccine Procedure | Payment Allowance | Effective From | Effective To | Footnotes | My Fee |
---|---|---|---|---|---|---|
Regeneron | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | $450.00 | 2020-07-30 | 2022-01-24 | [3][6][9] | (your fee) |
[3] These rates will be geographically adjusted for many providers.
[6] On July 30, 2021, the FDA revised the EUA for casirivimab and imdevimab to allow its use for post-exposure prophylaxis (PEP) in certain adult and pediatric patients. For patients who meet the criteria for repeat dosing, the authorized dosage is an initial dose of 1200 mg, followed by subsequent repeat dosing of 600 mg once every 4 weeks for the duration of ongoing exposure. As a result, CMS issued a new product code for casirivimab and imdevimab of 600 mg (Q0240), and 2 new codes for the administration of repeat doses of casirivimab and imdevimab (M0240/M0241). Providers and suppliers who administer casirivimab and imdevimab for PEP should use M0243 or M0244 for administering the first dose and M0240 or M0241 for administering subsequent repeat doses.
[9] On January 24, 2022, the FDA announced that, due to the high frequency of the Omicron variant, this product isn’t currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.
Learn more at: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies
This section shows APC information including: Status Indicator, Relative Weight, Payment Rate, Crosswalks, and more. Access to this feature is available in the following products:
|
View fees for this code from 4 different built-in fee schedules and from those you've added using the Compare-A-Fee™ tool. If you work with several fee schedules or would like to create custom fee comparison reports, you need our exclusive Compare-A-Fee™ tool.
|
View a table of UCR, Worker's Comp, and Medicare Fees here, as well as see UCR Fees in the charts below. Access to this feature is available in the following products:
Note: Subscribers will see the fee graphs below. |
View a chart showing the last 8+ years of Medicare denial rates, Medicare Allowed amounts, and Medicare billed amounts. Access to this feature is available in the following products:
Note: Subscribers will see the fee graphs below. |
Thank you for choosing Find-A-Code, please Sign In to remove ads.